• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » ISI Acquires Apyx to Bolster Services

ISI Acquires Apyx to Bolster Services

November 18, 2009
CenterWatch Staff

Whippany, N.J.-based ISI, a provider of software and services for the life sciences industry, has acquired Apyx in an effort to boost ISI’s services business.

The acquisition helps ISI strengthen its capabilities to offer clients a mix of process, technology, data and operational services in a complex regulatory submission environment. ISI’s professional services business already saw a 26% increase in sales from 2007 to 2008.

“This addition to ISI enhances our flexible and holistic suite of services and software to the regulatory space,” said Jinsoo Kim, president and CEO of ISI. “Industry leadership and experience from Apyx helps fuel our mission of helping bring life-changing therapies to market safely and efficiently.”

ISI currently provides 13 out of the top 20 pharmaceutical companies with ongoing services. In the last decade, the company has helped biopharmaceutical companies bring dozens of therapies through regulatory approval. Founded in 1992, ISI provides submissions solutions, process services and consulting to life sciences companies as a way to improve clinical and regulatory processes. ISI was among the first professional services firms to deliver electronic submissions to the industry.

The company said its strategic focus is on submissions, but it also offers clinical data management services, such as annotation of case report forms, manipulation of SAS data, and integration of multiple data formats.  In addition, ISI provides statistical analysis, data set review and statistical writing services. 

ISI has 455 employees in the U.S., Europe, China, and Korea, and Apyx adds 20 employees.

ISI makes the Apyx acquisition at a time of regulatory uncertainty for the pharmaceutical industry. Changing regulatory standards across regions, the need to expand into emerging markets, and increasing pressure to collaborate with partners and oversee local operations are all contributing to the new era of complexity.

“We are joining forces with ISI because there is a huge opportunity to leverage each other’s strengths,” said Ken VanLuvanee, CEO, president and founder of Apyx. “With ISI’s deep resources and expertise in Europe and Asia, we will be able to address the diverse range of submission requirements across the globe.”

VanLuvanee becomes ISI’s vice president of Global Professional Services, reporting to Paul Chung, executive vice president. VanLuvanee will be leading the effort to further expand ISI’s professional services capabilities, using his prior experiences within the consulting business around document management, business process improvement, Clinical Data Interchange Standards Consortium (CDISC) submission services and program management. He will continue to be an active contributor at various industry forums and various standards’ development initiatives.

ISI is a CDISC-registered solutions provider.  ISI encourages sponsor organizations to embrace the standards as early as possible in the process, providing implementation and validation services along the way, such as supporting electronic data capture for clinical trials directly under newer data content standards.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing